References:
Bear HD et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366(4):310-20. Abstract
Gwin K et al. Breast carcinoma with chondroid differentiation: A clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases. Int J Surg Pathol 2010;18(1):27-35. Abstract
Lobo C et al. Paclitaxel albumin-bound particles (Abraxane) in combination with bevacizumab with or without gemcitabine: Early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed Pharmacother 2007;61(9):531-3. Abstract
Nieto Y et al. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. Cancer Chemother Pharmacol 2010;65(3):457-65. Abstract
Ocaña A et al. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer 2006;6(6):495-504. Abstract
Overmoyer BA. Chemotherapeutic palliative approaches in the treatment of breast cancer. Semin Oncol 1995;22(2 Suppl 3):2-9. Abstract
Robert NJ et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-60. Abstract
Sánchez-Muñoz A et al. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: Results from a phase II trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients. Am J Clin Oncol 2010;33(5):432-7. Abstract
Smith IE et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2,251 patients. Ann Oncol 2011;22(3):595-602. Abstract
Yardley DA. Visceral disease in patients with metastatic breast cancer: Efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer 2010;10(1):64-73. Abstract